What Is BioMarin Pharmaceutical Inc. (BMRN) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, BioMarin Pharmaceutical Inc.'s intrinsic value is estimated at $41.21, suggesting the stock is overvalued at its current price of $59.20. With 11 out of 13 models flagging downside (-30.4% average return), the market may be pricing in unsustainable growth. The most optimistic model, First Chicago, places fair value at $108.42 (+83.1%), while EPV — the most conservative — estimates $8.85 (-85.1%). This +168.2% gap reflects genuine analytical uncertainty about BioMarin Pharmaceutical Inc.'s intrinsic worth. Among models with highest confidence, Markov DDM lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About BMRN?
13 of 13 models are currently active for BMRN. Of these, 2 models suggest upside while 11 models suggest overvaluation. The Bayesian DCF estimates BMRN's intrinsic value at $24.28, implying -59.0% downside from the current price. See which stocks rank higher →
How Does BMRN Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, BMRN ranks #14 by Quality of Company score. CirclFi's QOC score of 9.4/10 evaluates 32 fundamental signals. A score of 9.4 places BMRN in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a pharmaceutical industry, BioMarin Pharmaceutical Inc. operates in a sector where revenue per drug is a critical driver of valuation. Investors evaluating BMRN should weigh these sector-specific dynamics alongside our model-derived fair values.
Is BMRN a Value Trap?
The Value Trap algorithm is not active for BMRN. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for BioMarin Pharmaceutical Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, BioMarin Pharmaceutical Inc.'s fundamental quality profile registers 9.4/10. This exceptional score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +168.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BMRN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BMRN's 13 active models, average confidence is 48%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad